Stay updated with breaking news from Jaffe Laboratories. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The "Bioprosthetics Market Research Report by Type, Application, and Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" report...
We at Insider Monkey have gone over 866 13F filings that hedge funds and prominent investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of March 31st. In this article, we look at what those funds think of Good Times Restaurants Inc. (NASDAQ:GTIM) based on […]
Provided by Accesswire Apr 23, 2021 4:40 PM UTC IRVINE, CA / ACCESSWIRE / April 23, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI's first-in-human VenoValve® study in Bogota, Colombia, presented one year data this past week at the Charing Cross International Symposium. The Charing Cross International Symposium is the longest-running vascular and endovascular global symposium in Europe and is attended by the wor...
Hancock Jaffe Laboratories, Inc.: Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium April 23, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI's first-in-human VenoValve® study in Bogota, Colombia, presented one year data this past week at the Charing Cross International Symposium. The Charing Cross International Symposium is the l...
Hancock Jaffe Laboratories, Inc.: First U.S. Patent Issues on Hancock Jaffe VenoValve / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the United States Patent and Trademark Office (USPTO) has issued the first patent covering the company's VenoValve. The patent is entitled Implantable Vein Frame and is U.S. patent number 10,959,841. The company recently announced that only twenty-eight (28) days after filing, the U.S. Food and Drug Administration (FDA) approved the company's Investigational Devic...